Establishing an Approach for Designation of Evolving and Emerging Drug Threats

Affiliations

¹ Michael A. Ashburn, MD, MPH, MBA, is a Professor, Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA and is Senior Policy Analyst, White House Office of National Drug Control Policy, Washington, DC.
² David R. Holtgrave, PhD, is Assistant Director for Translational Research, White House Office of National Drug Control Policy, Washington, DC.
³ Richard J. Baum, MA, MPA, is a Senior Policy Analyst, Emerging Threats, White House Office of National Drug Control Policy, Washington, DC.
⁴ Rahul Gupta, MD, MPH, MBA, is Director, White House Office of National Drug Control Policy, Washington, DC.

Michael A Ashburn et al. Health Secur. 2023 May-Jun.

. 2023 May-Jun;21(3):239-241.

doi: 10.1089/hs.2022.0150. Epub 2023 Mar 21.

¹ Michael A. Ashburn, MD, MPH, MBA, is a Professor, Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA and is Senior Policy Analyst, White House Office of National Drug Control Policy, Washington, DC.
² David R. Holtgrave, PhD, is Assistant Director for Translational Research, White House Office of National Drug Control Policy, Washington, DC.
³ Richard J. Baum, MA, MPA, is a Senior Policy Analyst, Emerging Threats, White House Office of National Drug Control Policy, Washington, DC.
⁴ Rahul Gupta, MD, MPH, MBA, is Director, White House Office of National Drug Control Policy, Washington, DC.

No abstract available

Keywords: Drug use prevalence; Drug use prevention; Emerging drug threats; Emerging drug trends; National strategy/policy.

MeSH terms